Shift Pharmaceuticals Employee Directory
Pharmaceutical ManufacturingKansas, United States2-10 Employees
Shift Pharmaceuticals is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders, including Charcot Marie Tooth Syndrome (CMT1A) and Spinal Muscular Atrophy (SMA). Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease. We are supported with funding from the NIH, DoD, CMT Research Foundation, and Gwendolyn Strong Foundation.